Liminatus Pharma, Inc.
LIMN- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001971387
No open-market purchases or sales by Liminatus Pharma, Inc. insiders were filed in the last 90 days; 14 institutions reported holding it in 13F filings for Q2 2026, worth $105.1K in total; no superinvestor holds it.
Other share classesLIMNW
Q2 2026 vs. Q1 2026
How the institutions holding Liminatus Pharma, Inc. changed between Q1 2026 and Q2 2026.
All holders in Q2 2026All holders in Q1 2026
| Measure | Q1 2026 | Q2 2026 | Change |
|---|---|---|---|
| Holders | 15 | 14 | −1 |
| Shares | 1.48M | 946.0K | −529.5K (−35.9%) |
| Value | $253.8K | $105.1K | −$148.7K (−58.6%) |
New holders (4)
Institutions that held Liminatus Pharma, Inc. at the end of Q2 2026 but not at the end of Q1 2026.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| XTX Topco Ltd | 221,839 | $24.5K | 0.00% |
| Goldman Sachs Group Inc | 40,220 | $4.44K | 0.00% |
| StoneX Group Inc. | 26,058 | $3.93K | 0.00% |
| Barclays PLC | 4,290 | $474 | 0.00% |
Sold out (5)
Institutions that held Liminatus Pharma, Inc. at the end of Q1 2026 and filed for Q2 2026 without it.
| Institution | Shares, Q1 2026 | Value, Q1 2026 |
|---|---|---|
| Jane Street Group, LLC | 71,318 | $12.3K |
| Virtu Financial LLC | 27,468 | $5.00K |
| Two Sigma Securities, LLC | 22,039 | $3.79K |
| Citigroup Inc | 6,769 | $1.16K |
| Farther Finance Advisors, LLC | 14 | $2 |